The committee will be asked to discuss new drug application (NDA) 022034, for vernakalant HCl solution, for intravenous injection, submitted by Correvio International Sàrl, for the proposed indication of rapid conversion of recent onset atrial fibrillation to sinus rhythm for non-surgery patients: Atrial fibrillation ≤ 7 days duration, and for post-cardiac surgery patients: Atrial fibrillation ≤ 3 days duration.
Back to All Events
Earlier Event: November 14
Endocrinologic and Metabolic Drugs Advisory Committee
Later Event: December 13
Dermatologic and Ophthalmic Drugs Advisory Committee